Drug Profile
Gosuranemab - Biogen
Alternative Names: Anti-eTau; Anti-etau humanised IGG4 monoclonal antibody - Biogen; Anti-tau-mAb; BIIB092; BMS-986168; IPN-007Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator iPierian
- Developer Biogen; Bristol-Myers Squibb; iPierian
- Class Antidementias; Monoclonal antibodies
- Mechanism of Action Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Cardiovascular disorders; Metabolic disorders; Neurodegenerative disorders; Progressive supranuclear palsy
Most Recent Events
- 26 Jul 2021 Efficacy and adverse events data from a phase Ib trial in in Neurodegenerative disorders (Tauopathies) presented at the Alzheimer's Association International Conference 2021 (AAIC-2021)
- 16 Jun 2021 Discontinued - Phase-II for Alzheimer's disease in USA, Sweden, Spain, Australia, Poland, Japan, Italy, France and Germany (IV) (NCT03352557)
- 16 Jun 2021 Adverse events and efficacy data from a phase II trial for Alzheimer's disease released by Biogen